TiumBio
Seongnam · Founded 2016
About TiumBio
TiumBio is an R&D company that creates innovative new drugs. The company provides services for cancer, hemophilia, type 2 diabetes, and idiopathic pulmonary fibrosis. TiumBio develops NCE401, NCE403, NBP604, and NBP611. NCE401 is a substance for the treatment of fibrosis while NCE403 is for treating endomitriosis, NBP604 is for hemophilia and works a neutralizing antibody, and lastly NBP611, for the treatment of hemophilia B.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $51.6M
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2023)
- Ticker: kosdaq:321550
- Website: tiumbio.com
- Phone: +81 31-600-1500
Industries & Categories
Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/tiumbio-210259 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.